Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.33 |
| ▸ | MC4R | P32245 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | MLNR | O43193 | 1/20 | 0.33 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10689462 | 0.84 | ALOX5 (0.33) | ALOX5CES2CES1KEAP1CNR2 | |
| SCHEMBL17789887 | 0.82 | MAPT (0.33) | ALOX5CES2CES1KEAP1CNR2 | |
| SCHEMBL15853757 | 0.79 | — | — | |
| SCHEMBL5911168 | 0.79 | — | — | |
| SCHEMBL14511482 | 0.77 | — | — | |
| SCHEMBL10814543 | 0.77 | — | — | |
| SCHEMBL3272010 | 0.77 | — | — | |
| SCHEMBL20604453 | 0.77 | CES2 (0.44) | ALOX5CES2CES1KEAP1CNR2 | |
| SCHEMBL20604450 | 0.77 | CES2 (0.44) | ALOX5CES2CES1KEAP1CNR2 | |
| SCHEMBL8409514 | 0.76 | ALOX5 (0.36) | ALOX5CES2CES1KEAP1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014078197-A1 | 2-THIO-1,3,4-OXADIAZOLES DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS | ALLERGAN, INC. (US) | 2014-05-22 | — | — | WO | disclosed |
| US-20130065897-A1 | COMPOUNDS, PREPARATION AND USES THEREOF | PETER MACCALLUM CANCER INSTITUTE (AU) | 2013-03-14 | — | — | US | disclosed |
| EP-2515903-A1 | COMPOUNDS, PREPARATIONS AND USES THEREOF | Peter MacCallum Cancer Institute (AU) | 2012-10-31 | — | — | EP | disclosed |
| WO-2011075784-A1 | COMPOUNDS, PREPARATIONS AND USES THEREOF | PETER MACCALLUM CANCER INSTITUTE (AU) | 2011-06-30 | — | — | WO | disclosed |
| CN-1324212-A | Methods of treating or preventing viral infections and related diseases | VIROPHARMA INC (US) | 2001-11-28 | — | — | CN | disclosed |
| WO-1996014302-A1 | PYRAZOLE DERIVATIVES EXHIBITING ANTI-INFLAMMATORY AND ANALGESIC EFFECTS | EISAI CO., LTD. (JP) | 1996-05-17 | — | — | WO | disclosed |
| US-5260319-A | Analgesics | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1993-11-09 | — | — | US | disclosed |
| US-5234946-A | Anticholesterol, antilipemic | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1993-08-10 | — | — | US | disclosed |
| US-5227388-A | Analgesics | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1993-07-13 | — | — | US | disclosed |
| EP-0435223-A2 | Thienobenzoxepin- and naphthothiophene-derivatives, a process and intermediates for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1991-07-03 | — | — | EP | disclosed |
| US-5006536-A | Thienobenzoxepins and analgesic compositions thereof | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1991-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065897-A1 | COMPOUNDS, PREPARATION AND USES THEREOF | PRF1, GZMB, SERPINB1 | ALOX5 423/4885CES2 2930/4885CES1 1662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.